Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Richter transformation (RT) refers to the occurrence of an aggressive and treatment-resistant lymphoma that arises from the progression of chronic lymphocytic leukemia (CLL) and is associated with a ...

(Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon ...

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of ...

BCL6 overexpression drives lymphomagenesis and immune evasion in B-cell malignancies. This Patent Highlight presents novel bifunctional degraders targeting BCL6, demonstrating high potency and ...

Get Instant Summarized Text (Gist) The study mapped age-related changes in the immune system with unprecedented detail, analyzing immune profiles of 550 older and 100 younger participants. It ...

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

A 66-year-old Chinese woman was presented to our hospital on November 28, 2023, with a three-day history of abdominal pain. The patient had no significant medical history. No personal or family ...